In yesterday’s Wall Street session, Applied Therapeutics Inc. (NASDAQ:APLT) shares traded at $1.92, up 12.28% from the previous session.
As of this writing, 2 analysts cover Applied Therapeutics Inc. (NASDAQ:APLT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $5.00, we find $9.50. Given the previous closing price of $1.71, this indicates a potential upside of 455.56 percent. APLT stock price is now 35.72% away from the 50-day moving average and 76.57% away from the 200-day moving average. The market capitalization of the company currently stands at $111.86M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.50 as their price target over the next twelve months.
With the price target reduced from $44 to $7, Barclays Downgraded its rating from Overweight to Equal Weight for Applied Therapeutics Inc. (NASDAQ: APLT).
In other news, Shendelman Shoshana, President and CEO sold 15,870 shares of the company’s stock on Jan 11. The stock was sold for $14,442 at an average price of $0.91. Upon completion of the transaction, the President and CEO now directly owns 751,625 shares in the company, valued at $1.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 11, Chief Medical Officer Perfetti Riccardo sold 6,053 shares of the business’s stock. A total of $5,508 was realized by selling the stock at an average price of $0.91. This leaves the insider owning 154,856 shares of the company worth $0.3 million. Insiders disposed of 26,418 shares of company stock worth roughly $50722.56 over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APLT stock. A new stake in Applied Therapeutics Inc. shares was purchased by SIMPLIFY ASSET MANAGEMENT INC. during the first quarter worth $4,575,000. WEALTHTRUST AXIOM LLC invested $83,000 in shares of APLT during the first quarter. In the first quarter, US BANCORP DE acquired a new stake in Applied Therapeutics Inc. valued at approximately $35,000. ESSEX FINANCIAL SERVICES, INC. acquired a new stake in APLT for approximately $19,000.
Wednesday morning saw Applied Therapeutics Inc. (NASDAQ: APLT) opened at $1.7000. During the past 12 months, Applied Therapeutics Inc. has had a low of $0.50 and a high of $2.18. The fifty day moving average price for APLT is $1.4233 and a two-hundred day moving average price translates $1.0942 for the stock.
According to the Biotechnology Company, earnings per share came in at -$0.18, beating analysts’ expectations of -$0.31 by 0.13. This compares to -$0.88 EPS in the same period last year. For the current quarter, analysts expect APLT to generate $8M in revenue.
